161 related articles for article (PubMed ID: 27118408)
21. The myopathy-causing mutation DNM2-S619L leads to defective tubulation in vitro and in developing zebrafish.
Gibbs EM; Davidson AE; Telfer WR; Feldman EL; Dowling JJ
Dis Model Mech; 2014 Jan; 7(1):157-61. PubMed ID: 24135484
[TBL] [Abstract][Full Text] [Related]
22. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.
Böhm J; Biancalana V; Malfatti E; Dondaine N; Koch C; Vasli N; Kress W; Strittmatter M; Taratuto AL; Gonorazky H; Laforêt P; Maisonobe T; Olivé M; Gonzalez-Mera L; Fardeau M; Carrière N; Clavelou P; Eymard B; Bitoun M; Rendu J; Fauré J; Weis J; Mandel JL; Romero NB; Laporte J
Brain; 2014 Dec; 137(Pt 12):3160-70. PubMed ID: 25260562
[TBL] [Abstract][Full Text] [Related]
23. Clinical, pathological, and genetic features of dynamin-2-related centronuclear myopathy in China.
Chen T; Pu C; Wang Q; Liu J; Mao Y; Shi Q
Neurol Sci; 2015 May; 36(5):735-41. PubMed ID: 25501959
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2.
Mori-Yoshimura M; Okuma A; Oya Y; Fujimura-Kiyono C; Nakajima H; Matsuura K; Takemura A; Malicdan MC; Hayashi YK; Nonaka I; Murata M; Nishino I
Clin Neurol Neurosurg; 2012 Jul; 114(6):678-83. PubMed ID: 22613877
[TBL] [Abstract][Full Text] [Related]
25. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
26. Subtle central and peripheral nervous system abnormalities in a family with centronuclear myopathy and a novel dynamin 2 gene mutation.
Echaniz-Laguna A; Nicot AS; Carré S; Franques J; Tranchant C; Dondaine N; Biancalana V; Mandel JL; Laporte J
Neuromuscul Disord; 2007 Dec; 17(11-12):955-9. PubMed ID: 17825552
[TBL] [Abstract][Full Text] [Related]
27. Novel dynamin 2 mutations in adult T-cell acute lymphoblastic leukemia.
Ge Z; Li M; Zhao G; Xiao L; Gu Y; Zhou X; Yu MD; Li J; Dovat S; Song C
Oncol Lett; 2016 Oct; 12(4):2746-2751. PubMed ID: 27698851
[TBL] [Abstract][Full Text] [Related]
28. Identification of DeltaEF1 as a novel target that is negatively regulated by LMO2 in T-cell leukemia.
Sun W; Yang S; Shen W; Li H; Gao Y; Zhu TH
Eur J Haematol; 2010 Dec; 85(6):508-19. PubMed ID: 20731704
[TBL] [Abstract][Full Text] [Related]
29. LMO2 at 25 years: a paradigm of chromosomal translocation proteins.
Chambers J; Rabbitts TH
Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
[TBL] [Abstract][Full Text] [Related]
30. The LMO2 oncogene regulates DNA replication in hematopoietic cells.
Sincennes MC; Humbert M; Grondin B; Lisi V; Veiga DF; Haman A; Cazaux C; Mashtalir N; Affar el B; Verreault A; Hoang T
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1393-8. PubMed ID: 26764384
[TBL] [Abstract][Full Text] [Related]
31. Mutations that collaborate with IL-7Ra signaling pathways to drive ALL.
Rodrigues GOL; Cramer SD; Winer HY; Hixon JA; Li W; Yunes JA; Durum SK
Adv Biol Regul; 2021 May; 80():100788. PubMed ID: 33578108
[TBL] [Abstract][Full Text] [Related]
32. Role of dynamin 2 in the disassembly of focal adhesions.
Briñas L; Vassilopoulos S; Bonne G; Guicheney P; Bitoun M
J Mol Med (Berl); 2013 Jul; 91(7):803-9. PubMed ID: 23609221
[TBL] [Abstract][Full Text] [Related]
33. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
Kim SH; Kim EJ; Hitomi M; Oh SY; Jin X; Jeon HM; Beck S; Jin X; Kim JK; Park CG; Chang SY; Yin J; Kim T; Jeon YJ; Song J; Lim YC; Lathia JD; Nakano I; Kim H
Cell Death Differ; 2015 Sep; 22(9):1517-25. PubMed ID: 25721045
[TBL] [Abstract][Full Text] [Related]
34. A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.
Trochet D; Bitoun M
J Exp Clin Cancer Res; 2021 Jul; 40(1):238. PubMed ID: 34294140
[TBL] [Abstract][Full Text] [Related]
35. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome.
Koutsopoulos OS; Kretz C; Weller CM; Roux A; Mojzisova H; Böhm J; Koch C; Toussaint A; Heckel E; Stemkens D; Ter Horst SA; Thibault C; Koch M; Mehdi SQ; Bijlsma EK; Mandel JL; Vermot J; Laporte J
Eur J Hum Genet; 2013 Jun; 21(6):637-42. PubMed ID: 23092955
[TBL] [Abstract][Full Text] [Related]
36. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
37. Mutations in dynamin 2 cause dominant centronuclear myopathy.
Bitoun M; Maugenre S; Jeannet PY; Lacène E; Ferrer X; Laforêt P; Martin JJ; Laporte J; Lochmüller H; Beggs AH; Fardeau M; Eymard B; Romero NB; Guicheney P
Nat Genet; 2005 Nov; 37(11):1207-9. PubMed ID: 16227997
[TBL] [Abstract][Full Text] [Related]
38. LMO2 induces T-cell leukemia with epigenetic deregulation of CD4.
Cleveland SM; Goodings C; Tripathi RM; Elliott N; Thompson MA; Guo Y; Shyr Y; Davé UP
Exp Hematol; 2014 Jul; 42(7):581-93.e5. PubMed ID: 24792354
[TBL] [Abstract][Full Text] [Related]
39. Dynamin-2 mediates heart failure by modulating Ca2+ -dependent cardiomyocyte apoptosis.
Li J; Zhang DS; Ye JC; Li CM; Qi M; Liang DD; Xu XR; Xu L; Liu Y; Zhang H; Zhang YY; Deng FF; Feng J; Shi D; Chen JJ; Li L; Chen G; Sun YF; Peng LY; Chen YH
Int J Cardiol; 2013 Oct; 168(3):2109-19. PubMed ID: 23410488
[TBL] [Abstract][Full Text] [Related]
40. A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: clinical and pathological findings.
Bitoun M; Stojkovic T; Prudhon B; Maurage CA; Latour P; Vermersch P; Guicheney P
Neuromuscul Disord; 2008 Apr; 18(4):334-8. PubMed ID: 18394888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
